We wish to thank the following industry partners for their confirmed support to the BRS Annual Meeting 2023.
More companies are expected to support and exhibit at BRS 2023, so please visit this page regularly for an updated list of supporters.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
We are UCB, a global biopharmaceutical company dedicated to discovering and developing treatments that aim to transform the lives of people living with neurological, immunological and osteoporotic conditions.
For further information regarding our company, please visit https://www.ucbpharma.co.uk/
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
https://alexion.com/worldwide/UK
M/UK/UNB-U/0219 Date of preparation: March 2023
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton.
We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity.
You can learn more about the business of Kyowa Kirin at:
https://international.kyowa-kirin.com/uk/
Scanco Medical (www.scanco.ch), based in Zurich, Switzerland (since 1988) is the leading global provider of mCT and the HR-pQCT (XtremeCT) systems. Specimen scanners offer industry leading high-resolution and large specimen size capabilities and include a high-capacity automatic sample loading carousel enabling a high throughput workflow. All systems are bundled with easy to use and comprehensive software for image acquisition and analysis including Finite Element Analysis (optional), visualization and archiving running on Windows ® based workstations (except XtremeCT). Scanco also provides contract-based scanning and analysis services for academic and industrial groups. Contact us for a free and no-obligation demonstration.
Wonderful Scientific Limited is the proud distributor of Neoscan.com benchtop Micro-CT products in the UK and Ireland. The N80 scanner is the best in class scanner and ideal for high resolution bone analysis and visualisation of osteocyte lacunae. The N80 has a sealed transmission X-ray source with a 2um spot size and movable target repositioning, radiation hardened camera protection, 2: fibre optics, active artefact suppression, new precision stepper motors and all new software. The resulting benefits make it the most robust, long lasting, advanced and highest resolution benchtop product on the market today.
https://www.wonderfulscientific.com
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
https://alexion.com/worldwide/UK
M/UK/UNB-U/0219 Date of preparation: March 2023
Ipsen was first established as a business in the UK in 1981, and in Ireland in 1989. Today, the UK & Ireland forms a critical and growing part of our Global network and is one of our core operating hubs alongside Cambridge, M.A., USA and Paris, France. As a UK & Ireland Hub we are collaborating to deliver outcomes for patients, health services and our community of current and future colleagues.​​ Three of Ipsen’s leading medicines are manufactured in the UK & Ireland, with our UK footprint also ‘home’ to the global neuroscience franchise, with research, development, and manufacturing capabilities located across our Milton Park (Oxford) and Wrexham facilities.
The UK & Ireland Hub is home to over 850 colleagues located across four sites, offering a rich environment for development and career opportunity. Improving the lives of patients is what drives us, with the search for innovative solutions to disabling conditions at the heart of everything we do, in our three chosen areas of speciality care – oncology, neuroscience and rare disease.
https://www.ipsen.com/uk-ireland/
DRSC-UK-000130 Date of preparation: March 2023
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity.
You can learn more about the business of Kyowa Kirin at:
https://international.kyowa-kirin.com/uk/
For further information and queries about sponsorship and exhibiting opportiunities, please contact the BRS Event Team:
